


Article

Cell

Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement

Graphical Abstract



Authors

Hani Goodarzi, Xuhang Liu, ..., Lisa Fish, Sohail F. Tavazoie

Correspondence

stavazoie@mail.rockefeller.edu

In Brief

tRNA-derived fragments produced under hypoxic stress act as tumor suppressors through a post-transcriptional mechanism that leads to destabilization of many pro-oncogenic transcripts. Highly metastatic cells are capable of evading this mechanism by blunting the induction of tRFs during hypoxic conditions associated with cancer progression.

Highlights

- Hypoxic stress induces the production of tRNA-derived fragments (tRFs)
- This class of tRFs suppresses the development of breast cancer metastasis
- tRFs bind to oncogenic RNA-binding protein YBX1, displacing pro-oncogenic transcripts
- Highly metastatic cells blunt the induction of the tRFs during hypoxia

Accession Numbers

GSE63605



Goodarzi et al., 2015, Cell 161, 790–802
May 7, 2015 ©2015 Elsevier Inc.
<http://dx.doi.org/10.1016/j.cell.2015.02.053>

CellPress

Endogenous tRNA-Derived Fragments Suppress Breast Cancer Progression via YBX1 Displacement

Hani Goodarzi,¹ Xuhang Liu,¹ Hoang C.B. Nguyen,¹ Steven Zhang,¹ Lisa Fish,¹ and Sohail F. Tavazoie^{1,*}

¹Laboratory of Systems Cancer Biology, Rockefeller University, New York, NY 10065, USA

*Correspondence: stavazoie@mail.rockefeller.edu

<http://dx.doi.org/10.1016/j.cell.2015.02.053>

SUMMARY

Upon exposure to stress, tRNAs are enzymatically cleaved, yielding distinct classes of tRNA-derived fragments (tRFs). We identify a novel class of tRFs derived from tRNA^{Glu}, tRNA^{Asp}, tRNA^{Gly}, and tRNA^{Tyr} that, upon induction, suppress the stability of multiple oncogenic transcripts in breast cancer cells by displacing their 3' untranslated regions (UTRs) from the RNA-binding protein YBX1. This mode of post-transcriptional silencing is sequence specific, as these fragments all share a common motif that matches the YBX1 recognition sequence. Loss-of-function and gain-of-function studies, using anti-sense locked-nucleic acids (LNAs) and synthetic RNA mimetics, respectively, revealed that these fragments suppress growth under serum-starvation, cancer cell invasion, and metastasis by breast cancer cells. Highly metastatic cells evade this tumor-suppressive pathway by attenuating the induction of these tRFs. Our findings reveal a tumor-suppressive role for specific tRNA-derived fragments and describe a molecular mechanism for their action. This transcript displacement-based mechanism may generalize to other tRNA, ribosomal-RNA, and sno-RNA fragments.

INTRODUCTION

Transfer RNA-derived RNA fragments (tRFs) belong to a family of short non-coding RNAs (ncRNAs) present in most organisms. These RNAs can be both constitutively generated and produced in the context of stress. Constitutive tRFs are thought to arise from ribonucleolytic processing of tRNAs by Dicer (Cole et al., 2009) and RNase Z (Lee et al., 2009). The generation of stress-induced tRFs, also known as stress-induced fragments (tiRNAs), has been shown to occur via the action of specific ribonucleases such as Angiogenin (Fu et al., 2009). Although tRNAs are one of the most abundant ncRNA molecules in the cell (~10% of total cellular RNA), only a small fraction of tRNAs are cleaved to produce tRFs (Thompson and Parker, 2009). Multiple classes of tRFs have been identified in various cell types and organisms and induced by various conditions. These classes are defined by the position of the tRNA cleavage site that gives rise to

tRFs, and these classes include 5'- and 3'-tRNA halves (cleaved in the anti-codon loop), 5'- and 3'-tRFs (also known as 3'CCA tRF), and 3'U tRFs, among others (Gebetsberger and Polacek, 2013).

Stress-induced tRFs have been reported to mediate a stress response, which results in stress granule assembly and inhibition of protein synthesis (Emara et al., 2010). Moreover, these tRFs can impact a number of cellular functions, such as cell proliferation and mediating RNA inactivation through Argonaute engagement (Gebetsberger and Polacek, 2013). In this study, we sought to investigate whether tRFs could play a role in metastatic progression. We reasoned that tRFs could have roles in cancer progression analogous to those of specific microRNAs (Krol et al., 2010). We also reasoned that because hypoxia is a major stress encountered by cells during cancer progression, tRFs induced under hypoxic conditions may act to curb metastatic progression. By employing next-generation small-RNA (smRNA) sequencing, we identified a group of tRFs that were upregulated under hypoxia in breast cancer cells as well as in non-transformed mammary epithelial cells. Interestingly, highly metastatic breast cancer cells did not display induction of these tRFs under hypoxia, suggesting a potential role for these molecules in cancer progression. We identified a common sequence motif present in these hypoxia-induced fragments, suggesting they may interact with a common *trans* factor. By using one of these tRFs (tRF^{Glu}) as bait, we immunoprecipitated and identified the RNA-binding protein YBX1 as a *trans* factor whose mRNA-stabilizing activity is repressed by these fragments.

YBX1 is a versatile RNA-binding protein with a variety of interacting partners. It is involved in many key cellular pathways, and its genetic inactivation leads to embryonic lethality (Uchiumi et al., 2006). Importantly, it is highly overexpressed in multiple cancer types (Jürchott et al., 2010; Matsumoto and Bay, 2005; Wu et al., 2012). By combining molecular, biochemical, and computational approaches, we find that tRFs bind YBX1 and displace a number of known oncogenic transcripts from YBX1, thereby antagonizing YBX1 activity. YBX1 stabilizes these oncogenic transcripts and mediates their enhanced expression. The displacement of these oncogenic transcripts by tRFs represses their stability and expression—thereby suppressing metastatic progression.

RESULTS

Systematic Identification of tRFs in Breast Cancer Cells

Tumor cells encounter various cellular stresses during the course of cancer progression. A critical stress is reduced access to




Figure 1. Genome-wide Profiling of tRFs in Breast Cancer MDA-231 Cells under Normal and Hypoxic Conditions

(A) The linear motif SCUBYC was enriched in RNA fragments mapping to tRNA loci that were upregulated in MDA-parental cells, but not MDA-LM2 cells, under hypoxic conditions. Shown are the mutual information values and their associated Z scores for the discovered motif in both cell lines (Elemento et al., 2007). The enrichment score (positive for enrichment and negative for depletion), presented as logP (hypergeometric p value), is also shown as a heatmap with blue showing depletion and yellow showing enrichment of the SCUBYC motif among the sequences in each cluster. The red border marks statistical significance of the enrichment score.

(B) The levels of tRFs derived from tRNA^{Glu} were significantly enhanced under hypoxic conditions in MDA-parental cells but not in MDA-LM2 cells. The log fold-change was calculated from the smRNA sequencing data. The p value was calculated using Wilcoxon rank-sum test. Two exemplary tRFs that contain the SCUBYC motif are also indicated.

(C) Streptavidin beads were used to co-precipitate proteins interacting with a 3'-biotinylated synthetic tRF^{Glu} mimetic and scrambled oligonucleotide in vivo. YBX1 was identified as a potential interacting partner based on the identity of the annotated RNA-protein complexes enriched among the tRF^{Glu} co-precipitated RNA-binding proteins.

(D) 3'-biotinylated synthetic oligonucleotides were used to co-precipitate YBX1. In addition to the scrambled RNA, a tRNA^{Ala}-derived fragment, which does not carry the identified motif, was also included as control. Western blotting was performed to detect YBX1 in the eluate from each sample.

(E) MDA-LM2 cells were transfected with a 21 nt synthetic tRF^{Glu} mimetic (unlabeled), also shown are scrambled transfected mimetic and untransfected cells as controls. After crosslinking immunoprecipitation of endogenous YBX1, and radiolabeling of the RNA population, a strong interaction between the transfected tRF^{Glu} mimetic and endogenous YBX1 was observed.

Error bars in all panels indicate SEM unless otherwise specified.

oxygen, a condition known as hypoxia (Moyer, 2012; Wilson and Hay, 2011). Multiple regulatory programs are co-opted by tumor cells to counteract the negative impacts of hypoxic stress (Bristow and Hill, 2008). For example, the stabilization and activation of the transcription factor HIF1 α under hypoxia results in the activation of vascular endothelial growth factor (VEGF, angiogenesis; Shen and Kaelin, 2013), GLUT1 (glucose transport), and carbonic anhydrase IX (CA9, pH regulation; Semenza, 1999). Recently, it was reported that tRFs are produced under hypoxia and during other stress conditions (Fu et al., 2009). Given the ability of hypoxia to significantly modulate the regulatory landscape of the cell at both transcriptional and post-transcriptional levels, we searched for tRNA fragments with potential regulatory roles that are modulated under hypoxic conditions in cancer cells. To do so, we performed smRNA sequencing of breast cancer cells (MDA-MB-231, hereafter termed MDA-parental). We observed that a sizeable fraction (~4%) of the smRNA population originated from tRNAs and therefore could be categorized as tRFs. We observed > 10 smRNA reads mapping to each of more than 300 tRNA loci across these samples.

tRFs belong to a class of smRNAs that are generated through endonucleolytic cleavage of tRNAs (Gebetsberger and Polacek,

2013; Thompson and Parker, 2009). These fragments have been detected in bacteria, yeast, and mammalian cells under normal and stress conditions (Gebetsberger and Polacek, 2013; Lee et al., 2009). Although tRNA fragments were first detected in the urine of cancer patients more than three decades ago, and at the time were proposed to be oncogenic molecules (Borek et al., 1977; Speer et al., 1979), their roles and mechanisms of action during cancer progression remain uncharacterized.

Consistent with their potential roles in stress response, tRF levels in breast cancer cells significantly increased under hypoxia ($p < 1e-6$, Figure S1A). Interestingly, the induction of these fragments by hypoxia was significantly blunted in MDA-LM2 cells—a highly metastatic sub-population derived through in vivo selection from the MDA-parental population (Figure S1A; Minn et al., 2005). These findings suggested that highly metastatic cells evade the upregulation of these fragments under hypoxic conditions. Sequence analysis of the tRNAs with hypoxia-induced fragmentation revealed the significant enrichment of a common linear sequence motif (SCUBYC; Figure 1A). This motif was not significantly enriched in the tRNA loci whose fragments were upregulated in highly metastatic MDA-LM2 cells, further highlighting the absence of a concerted upregulation of these

tRFs in highly metastatic cells (Figures 1A and S1A). The identification of this sequence motif among hypoxia-induced tRFs in MDA-parental cells raised the possibility that this element serves as a binding site for a common *trans* factor that potentially interacts with these small ncRNAs in vivo. For example, among tRNA^{Glu}-derived fragments, which were significantly upregulated under hypoxia in MDA-parental but not MDA-LM2 cells, several tRF species carried instances of the SCUBYC sequence motif described above (Figure 1B). In order to identify the unknown *trans* factor that may recognize this sequence motif, we used synthetic oligonucleotides from tRNA^{Glu} as bait in an in vitro co-precipitation experiment. A 21 nt 3'-biotinylated oligonucleotide carrying an instance of the identified motif was immobilized on streptavidin beads and was subsequently used to co-precipitate the interacting protein complexes. A scrambled RNA was processed in parallel as the control to measure the co-precipitation of proteins above background. In-solution digestion followed by mass-spectrometry was employed to determine the identity of the co-precipitated proteins. Gene-set enrichment analysis revealed that proteins annotated as components of "ribonucleoprotein complex" and "stress granule complex" were significantly over-represented among co-precipitated proteins (Figure 1C). YBX1, which showed 5-fold enrichment above background (Figure S1B), is the only protein that shares both of these annotations (Figure 1C); as such, we chose to further study this RNA-binding protein as a candidate tRF-interacting protein. To validate this interaction, we performed reciprocal co-immunoprecipitations and detected binding of YBX1 to an exogenously transfected 3'-biotinylated tRF^{Glu} mimetic, but not to the scrambled RNA or tRF^{Ala} controls (Figure 1D). Consistently, we also detected the binding of endogenous YBX1 to the tRF^{Glu} mimetic, but not the scrambled RNA control (Figure 1E).

Specific tRFs Interact with YBX1

YBX1, a multifunctional RNA-binding protein and a member of the Y box-binding protein family, has been implicated in various aspects of RNA biology. Importantly, it is a known modulator of RNA translation and stability and has been implicated in tRNA^{Ala}-mediated inhibition of ribosomal activity in vivo (Ivanov et al., 2011). Consistently, while resolving YBX1-crosslinked RNAs on a polyacrylamide gel, we observed a prominent smRNA band in addition to longer RNA species interacting with YBX1 (Figures 1E and S1C). We hypothesized that in addition to tRF^{Glu}, which was used as bait to identify YBX1, YBX1 may also interact with a broader population of endogenous smRNAs in the cell. To generate a detailed and precise snapshot of genome-wide YBX1-RNA interactions across long- and short RNA species, we performed crosslinking immunoprecipitation of endogenous YBX1 followed by high-throughput sequencing (CLIP-seq) in human MDA-parental breast cancer cells. Analysis of the CLIP-seq data provided us with the first in vivo YBX1 transcript interactome revealing more than 4,000 endogenous transcripts bound by YBX1. The majority of YBX1-binding sites were localized to 3' untranslated regions (3' UTRs) and exons, whereas minimal binding was detected in 5' UTRs and in intronic sequences (Figure 2A). A large number of cellular processes and pathways, including RNA processing, translation, cell cycle, glucose catabolism, spindle organization, and additional key signaling and

stress-response pathways, were over-represented among the YBX1-bound transcripts (Figure S1D). The breadth and diversity of the YBX1 regulon (Figures S1E and S1F) highlight its role in RNA homeostasis and growth, as well as its importance for cellular response to internal and external stimuli.

Consistent with our observation regarding the interaction between tRF^{Glu} and YBX1 in vivo, high-throughput sequencing of the YBX1-crosslinked smRNAs (smRNA CLIP-seq) revealed that the majority of these CLIP-seq tags mapped to tRNA loci and represented tRFs (Figures 2A, S2A, and S2B). We observed that YBX1 interacts with a specific subset of tRFs present in these cells. For example, tRF^{GlyTCC} and tRF^{AspGTC}, both with relatively low cellular expression levels, displayed substantial binding to YBX1, whereas highly expressed fragments, tRF^{LysTTT} and tRF^{SerAGA}, were absent among the YBX1 smRNA CLIP-seq tags (Figure S2C). A more global comparison is provided in Figure 2B in which the relative abundance of tRNA fragments mapping to each tRNA locus in MDA-parental cells is shown relative to those from the YBX1 smRNA CLIP-seq. These findings reveal that the interactions between tRFs and YBX1 were not simply a function of tRF abundance in the cell and that YBX1 binding to tRFs is specific and dependent on factors other than tRF levels (e.g., sequence specificity). Based on our YBX1 smRNA CLIP-seq experiment, we identified a number of specific tRFs as most abundantly bound by YBX1; chief among them, the tRNA^{Glu}, tRNA^{Asp}, and tRNA^{Gly} fragments that mapped to the anticodon loops of these tRNAs and a tRNA^{Tyr}-derived fragment matching the intron-containing precursor of this tRNA (Figure 2C).

Transcriptomic profiling under normoxic and hypoxic conditions in both control and YBX1 knockdown cells revealed that in the MDA-parental breast cancer cells, YBX1-bound transcripts were significantly enriched among those downregulated under hypoxia in a YBX1-dependent manner (Figure 2D). This observation suggested the presence of a hypoxia-induced and YBX1-mediated post-transcriptional regulatory program. Gene-expression analysis of non-tumorigenic mammary epithelial MCF10a cells under hypoxia also showed an enrichment of YBX1-bound transcripts among the hypoxia-induced downregulated genes, further strengthening this hypothesis (Z score = 5.7; data not shown). More importantly, highly metastatic MDA-LM2 cells did not exhibit YBX1-dependent downregulated expression of the target transcripts under hypoxia, consistent with their lack of induction of specific hypoxia-induced tRFs (Figure 2D). Given that YBX1 did not show a significant change in expression in MDA-LM2 cells relative to the MDA-parental line (Figure S2D), we hypothesized that the observed enrichment may be mediated by tRFs, which are induced in poorly metastatic but not highly metastatic cells (Figure S1A).

Our findings described above reveal a direct physical interaction between tRNA^{Glu} fragments and YBX1 (Figures 1D and 1E). In order to validate the in vivo interaction between the other tRFs and YBX1, we developed a cell-based competition experiment, based on quantitative PCR (qPCR) assays of smRNAs, in which chemically synthesized tRF mimetics were used to compete with endogenous fragments for YBX1 binding in vivo. We designed specific primers for reliable qPCR-mediated detection of tRF^{Glu}, tRF^{Asp}, and tRF^{Gly} in this competition assay. Under




Figure 2. Endogenous YBX1 Interacts with a Large Regulon of Transcripts and smRNAs In Vivo

(A) Pie charts depicting the annotation of YBX1-binding sites obtained from immunoprecipitation of endogenous YBX1 from RNase-treated lysate of UV-irradiated MDA-parental cells followed by high-throughput sequencing of both long- and smRNAs.

(B) Relative frequency of reads mapped to each tRNA locus in MDA-parental smRNA sequencing and YBX1 smRNA CLIP-seq. The tRF species most abundantly bound by YBX1 are marked.

(C) Based on the YBX1 smRNA CLIP-seq results, four species of tRFs bound by YBX1 in vivo were identified. Shown are examples of tRNA structures for each species depicting the boundaries of the identified tRFs along with the YBX1-binding region based on smRNA YBX1 CLIP-seq read density at each position (also see Figure S2A). The gray nucleotides at the 3' end mark the presence of terminal CCA sequences. The dark gray highlights for tRNA^{TyrGTA} mark the leader and intronic sequences in the unprocessed tRNA. The longest identified forms of each tRF based on our high-throughput sequencing results are also indicated (gray highlight) along with the YBX1 smRNA CLIP-seq read density at each position (overlaid as a heatmap) indicating the YBX1-binding site.

(D) Gene-expression profiling of control and YBX1 knockdown cells was performed under normal and hypoxic conditions in both MDA-parental and MDA-LM2 backgrounds. The set of transcripts that was downregulated under hypoxia in a YBX1-dependent manner was identified for each cell line. Although YBX1-bound transcripts were significantly enriched among YBX1-dependent hypoxia-induced downregulated transcripts in MDA-parental cells, this enrichment was absent in the highly metastatic MDA-LM2 cells.

(E) qPCR-based validation of interactions between YBX1 and tRF^{AspGTC}, tRF^{GluYTC}, and tRF^{GlyTCC}. Cells transfected with exogenous tRF mimetics were subjected to UV crosslinking and YBX1 immunoprecipitation. The abundance of each tRF in the co-immunoprecipitated RNA population was then measured using a smRNA qPCR-based quantitation assay (n = 3–4).

Statistical significance is measured using a one-tailed Student's t test: *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars in all panels indicate SEM unless otherwise specified.

the assumption that exogenous tRFs effectively bind YBX1 in vivo (as was shown for tRF^{Glu}), we predicted that the increase in cellular levels of a specific tRF would result in the subsequent displacement of other tRNA fragments from the endogenous YBX1-bound RNA population. To test this hypothesis, we UV-irradiated cells transfected with synthetic tRFs or scrambled controls, immunoprecipitated YBX1 under stringent CLIP-seq conditions (Ule et al., 2005), and used qPCR to detect the abundance of each specific tRF in the YBX1-bound fraction. Consistent with active binding of YBX1 to synthetic tRFs, we observed that exogenous transfection of a given tRF led to depletion of the other as-

sayed endogenous tRF species in every case (Figure 2E). This quantitative assay demonstrates not only that these tRF species bind YBX1 but also that they compete for YBX1 binding in vivo. Moreover, as was the case for tRF^{Glu}, we used 3'-biotinylated short oligonucleotides mimicking tRF^{Asp} and tRF^{Gly} to co-immunoprecipitate interacting proteins from total cell lysates. We observed significant enrichment in endogenous YBX1 protein levels upon co-immunoprecipitation of the tRFs relative to a 3'-biotinylated scrambled oligonucleotide (Figure S2E). Importantly, we also observed a significant upregulation in tRF^{Glu}, tRF^{Asp}, and tRF^{Gly} under hypoxic conditions, quantified using tRF-specific

qPCR in both MDA-parental breast cancer cells and MCF10a non-transformed mammary epithelial cells (Figures S2F and S2G). Consistent with our prior findings, this induction was absent in metastatic MDA-LM2 cells (Figure S2H). While these YBX1-binding tRFs are constitutively expressed, their levels are enhanced in the context of hypoxic stress. This observation indicates that the tRFs identified here can be categorized as tRNA-derived stress-induced RNAs (tiRNAs) and likely play roles in stress responses. More importantly, the absence of their induction in highly metastatic MDA-LM2 cells highlights the potential suppressive roles they may play during breast cancer metastasis, in which tRFs must be antagonized for metastasis to progress.

tRF-Mediated Post-Transcriptional Modulation through YBX1

Previous studies have established a role for another class of tRNA fragments—tRNA 5'-halves (e.g., 5'-tiRNA^{Ala} and 5'-tiRNA^{Cys})—in translation inhibition. These fragments were found to cause translation initiation factors to disengage from mRNAs (Ivanov et al., 2011). This translational inhibition effect was shown to be YBX1 dependent. The molecular mechanism through which this previously identified class of tRFs modulates YBX1 interaction with translation initiation factors remains to be elucidated. YBX1 has also been implicated in other post-transcriptional regulatory programs, most notably transcript stability. We set out to test whether functional interactions between tRFs and YBX1 affect expression levels of endogenous transcripts. We envisioned two plausible molecular mechanisms through which tRFs may affect YBX1 binding to mRNAs in vivo (Figure S3A). First, in a tRF-mediated transcript engagement model, a given tRF may act as a guide RNA whereby the YBX1-tRF complex binds specific target transcripts based on sequence complementarity to the bound tRF, in a manner similar to miRNA-mediated binding of transcripts by Argonaute. In this scenario, reducing tRF levels would lead to reduced YBX1 binding of transcripts. Second, in a tRF-mediated transcript displacement model, YBX1 would interact with tRFs and mRNAs alike, in which case tRFs would be actively competing with endogenous transcripts for YBX1 binding. In this model, reducing tRF levels would lead to greater YBX1 binding of its target mRNAs. Importantly, in the transcript engagement model, mRNAs carrying the reverse-complement of the tRF sequence would be affected in terms of YBX1-binding abundance or expression, whereas in the transcript displacement model, only the transcripts that contain YBX1-binding motifs would be affected by tRF modulation. In order to distinguish between these two molecular mechanisms, we utilized synthetic anti-sense locked-nucleic acids (LNAs) targeting the YBX1-binding site (based on the smRNA CLIP-seq peaks; Figures S2A and S2B) on the most abundantly bound tRFs—namely, tRF^{Asp}, tRF^{Gly}, tRF^{Glu}, and tRF^{Tyr} (Figure 2B). We used specific anti-sense LNAs to bind and inhibit the endogenous forms of these tRFs individually in order to observe their effects on the transcriptome relative to a scrambled LNA control. Importantly, to specifically focus on transcripts impacted by tRF inhibition through their direct interaction with YBX1, we conducted whole-transcriptome profiling of both control and YBX1 knock-down cells transfected with anti-sense LNAs (Figure S3B).

We first sought to identify the YBX1-binding sequences on these four tRFs in order to observe the behavior of mRNAs carrying these sequences (transcript displacement model) or their complementary sequences (transcript engagement model). We made no assumptions about the YBX1-binding site on RNAs, instead opting to test all possible 8-mers (and their reverse complements) along the identified binding sites on each of the four tRFs (sequences shown in Figure 3A). Each 8-mer was assessed for (1) its enrichment (or that of its reverse complement sequence) in 3' UTRs of transcripts that were deregulated in a YBX1-dependent manner in each experiment (see Experimental Procedures) and (2) its enrichment among YBX1-binding sites on endogenous transcripts (YBX1 CLIP-seq). For each tRF, we successfully identified an 8-mer that was enriched in both (1) the 3' UTRs of transcripts upregulated (not downregulated) in a YBX1-dependent manner and (2) the YBX1 CLIP-sites on endogenous mRNAs (Figures 3A and 3B). Given that in each case, it was the specific 8-mer, rather than its reverse complement, that was functionally bound by YBX1 in vivo, the YBX1 modulation of transcript levels observed here is consistent with the model wherein tRFs displace transcripts from YBX1. In this competition-based model, the binding of specific tRFs to YBX1 is inhibited by LNA transfection, allowing free YBX1 to interact with YBX1-binding sites on endogenous transcripts. Increased YBX1 binding would result in higher transcript abundances, most likely through enhanced mRNA stabilization by YBX1 in vivo. Subsequently, we provide additional genomic, molecular, and biochemical evidence that supports this YBX1-dependent post-transcriptional mode of regulation.

In order to determine a consensus binding site for YBX1 on tRFs and mRNAs, we performed multiple alignments for the 8-mers that were independently identified for each tRF. The resulting sequence motif, named CU-box based on the prominence of a C and U at the second and third positions along the identified regular expression representation of the element (Figure 3C), was significantly enriched among CLIP-seq tags in both YBX1 smRNA ($p < 0.002$) and long RNA (mRNA) CLIP-seq datasets ($p < 10^{-80}$; Figure 3D). Importantly, this element resembles an in vitro YBX1-binding motif described previously (Figure S3C). Moreover, tracking cross-linking-induced mutation sites (CIMS; Zhang and Darnell, 2011), which mark protein-RNA interactions at single-nucleotide resolution, at and around CU-box elements (10 flanking nucleotides) across the YBX1 CLIP sites revealed that the cross-linked nucleotides were most frequent at the site of the motif (Figure S3D). This observation further supports a direct physical interaction between YBX1 and CU-box elements. Taken together, our results indicate that YBX1 interacts with both endogenous target transcripts and tRFs via the CU-box element. It should also be noted that the SCUBYC motif identified in Figure 1A constitutes a specific subset of the CU-box element described here (CompareACE score of 0.85). The commonality of the binding site would enable tRFs to competitively modulate the levels of YBX1 available for transcript binding, which would in turn affect the expression of a large set of target transcripts.

Competitive tRF Binding to YBX1 Results in Transcript Destabilization

In addition to the anti-sense LNA-mediated tRF loss-of-function experiments followed by transcriptomic profiling, we also




Figure 3. YBX1 Interacts with Long- and smRNAs via a Specific Linear Sequence Motif

(A) The transcripts upregulated upon anti-sense LNA transfections targeting each of the four identified tRFs were compared to the remainder of the transcriptome (background) to identify over-representation of specific sequence elements in their 3' UTRs. Here, we have shown the enrichment of specific 8-mers along each YBX1-bound tRF in the 3' UTRs of these transcripts as a heatmap, with yellow and blue showing the extent of enrichment and depletion, respectively (red and blue borders mark statistical significance). Also shown are the associated mutual information values and Z scores (Elemento et al., 2007). We have provided the sequence of each tRF and highlighted the identified 8-mers.

(B) These 8-mers were also required to be enriched among the YBX1-binding sites identified with CLIP-seq. We used a shuffled version of each YBX1-binding site to create a background set and tested the enrichment of each 8-mer in the YBX1-binding sites relative to shuffled controls.

(C) In order to infer a consensus element for YBX1 on these tRFs, the four significant 8-mers were aligned, and the possible nucleotides at each position were combined to build the CU box element represented as a regular expression.

(D) The CU box motif showed a significant enrichment in both long- and smRNA YBX1 CLIP-seq data sets relative to randomly shuffled sequences, indicating that YBX1 binds a common linear sequence motif on both short and long endogenous RNAs.

Error bars in all panels indicate SEM unless otherwise specified.

transfected control and YBX1 knockdown cells with synthetic tRF mimetics in gain-of-function experiments delineated in Figure S3E. For this, we performed two separate experiments; in one, we transfected control and YBX1 knockdown cells with the mimetics representing the long form of each identified tRF (Figures 2C and S2B), and in another, we used ~20 nucleotide short synthetic tRF mimetics containing the identified YBX1-binding sites. Although YBX1-bound transcripts (and transcripts with CU boxes in their 3' UTRs) were significantly upregulated upon LNA transfections (Figures 4A, S4A, and S4B), these transcripts were significantly downregulated in the context of tRF mimetic transfection in a YBX1-dependent manner (Figures 4B, 4C, S4C, and S4D). These observations reveal that (1) exogenously transfected tRF mimetics act as modulators of the YBX1 regulon, and (2) short tRF mimetics carrying the YBX1-binding site are sufficient for exerting this regulatory effect.

To determine whether the observed YBX1-dependent tRF-mediated modulations in YBX1 target transcripts' levels were occurring post-transcriptionally, we performed whole-genome

transcript stability measurements. Through α -amanitin-based inhibition of RNA polymerase II in anti-sense LNA-transfected control and YBX1 cells, we found that the observed increase in YBX1-targeted transcript abundance resulted from a significant enhancement of their stabilities in a YBX1-dependent manner (Figures 4D, S4E, and S4F). This observation further establishes the role of these YBX1-tRF interactions as a coherent and functional post-transcriptional regulatory program (Figure S4G). Importantly, the changes observed in the expression of YBX1-dependent transcripts upon transfection of anti-sense LNAs or tRF mimetics were significantly anti-correlated (Figure S4H). Further supporting this model, we also observed a reduction in total RNA bound to YBX1 upon transient transfection of an exogenous tRF^{Glu} mimetic (Figure S5A).

Target-Specific Validation of a Role for tRF-YBX1 in Transcript Destabilization

Whole-genome expression and stability measurements support a transcript displacement model for tRF-YBX1 interaction,




Figure 4. Endogenous Transcripts Bound by YBX1 Are Modulated by YBX1-Bound tRFs

In order to measure the post-transcriptional regulatory consequences of tRFs, gain-of-function and loss-of-function experiments were performed by transfecting synthetic tRF mimetics or inhibitory anti-sense LNAs, for each of the four YBX1-binding tRFs, in normal and YBX1 knockdown cells. Transcripts that were up- or downregulated in a YBX1-dependent manner were identified by comparing the gene-expression changes in normal cells relative to those in YBX1 knockdown cells (Figure S3). Transcripts that interact with YBX1 in vivo (determined from YBX1 CLIP-seq data) were significantly de-regulated upon modulations of tRF levels: (A) they were upregulated upon LNA-mediated inhibition of YBX1-binding tRFs; (B and C) they were downregulated in the presence of exogenously added short and long tRF mimetics (~60 and ~20 nucleotides, respectively; see Figure S2B), and (D) the observed upregulation in the LNA-transfected cells coincided with a significant increase in their stability. Whole-genome transcript stability measurements were performed in LNA-transfected cells using α -amanitin-mediated inhibition of RNA polymerase II followed by RNA extraction and profiling at 0 and 8 hr time points. In all data sets, the calculated mutual information values (in bits) and their associated p values are provided. Also shown are the enrichment scores, presented as logP (positive for enrichments and negative for depletions), where P is calculated from hypergeometric distribution (shown as a heatmap with blue and gold showing depletion and enrichment, respectively). The red and blue borders mark statistical significance of the enrichment/depletions. Error bars in all panels indicate SEM unless otherwise specified.

wherein tRFs effectively compete with endogenous transcripts for YBX1 binding. In order to independently validate our observations for a specific set of targets, we chose HMGA1, CD151, CD97, and TIMP3 for target-specific follow-up experimental validation based on pervasive in vivo interactions with YBX1 along their 3' UTRs (Figure 5A). Transfection of tRF-specific anti-sense LNAs significantly upregulated and stabilized these transcripts (Figures 5B and 5C). More importantly, their observed upregulation was abrogated in YBX1 knockdown cells (Figures 5B and 5C).

As mentioned earlier, under hypoxic conditions, in which the YBX1-bound tRFs were shown to be upregulated in MDA-parental cells (Figure 2C), we observed a concomitant downregulation of YBX1 target transcripts (Figure 2D). Importantly, this hypoxia-induced YBX1-dependent downregulation, which was absent in highly metastatic MDA-LM2 cells, was diminished once hypoxic cells were transfected with anti-sense LNAs (Figure S5B). We also observed a similar expression pattern for HMGA1, CD97, and TIMP3 transcripts when tested under hypoxia and normoxia in both control and YBX1 knockdown cells




Figure 5. YBX1 Target Transcripts and Their Response to Changes in tRF Levels

(A) YBX1 interacts with the 3' UTRs of HMGA1, CD151, CD97, and TIMP3. The last exon of the indicated transcripts are shown with mapped reads from experimental replicates of YBX1 CLIP-seq.

(B) Transfection of anti-sense LNAs against YBX1-binding tRFs resulted in the upregulation of HMGA1, CD151, CD97, and TIMP3 transcripts, in a YBX1-dependent manner, as determined by qPCR measurements.

(C) Similarly, transfecting anti-sense LNAs resulted in a significant stabilization of HMGA1, CD97, and TIMP3 transcripts in a YBX1-dependent manner. Whole-genome RNA stability measurements were performed using α -amanitin-mediated inhibition of RNA polymerase II (see [Experimental Procedures](#)).

(D) A GFP/mCherry dual-reporter assay was used to measure the effects of cloning HMGA1, CD97, and part of the TIMP3 3' UTRs downstream of mCherry using qRT-PCR. The 3' UTR of MAPK14, which is devoid of YBX1 tags, was included as a control. Consistent with our prior findings, LNA transfections resulted in a significant increase in relative mCherry expression in a YBX1-dependent manner.

(E) Exogenously added tRF mimetics, although showing no effect on MAPK14 abundance, resulted in a significant depletion of HMGA1, CD97, and TIMP3 transcripts from the YBX1 co-immunoprecipitated RNA population.

Statistical significance is measured using a one-tailed Student's *t* test: **p* < 0.05, ***p* < 0.01, and ****p* < 0.001. Error bars in all panels indicate SEM unless otherwise specified.

tRF-Mediated Modulation of Cancer Progression and Metastasis

YBX1 has been implicated in cancer progression. YBX1 overexpression is correlated with tumorigenic phenotypes and has also been shown to promote cancer

in MDA-parental and MDA-LM2 backgrounds (Figure S5C). Consistently, we found that the 3' UTR sequences of these transcripts cloned downstream of a bi-directional reporter construct were sufficient to confer YBX1-dependent upregulation of the reporter upon transfection of anti-sense LNAs targeting the four selected tRFs (Figure 5D). The MAPK14 3' UTR, which was not bound by YBX1 as assessed by CLIP-seq, served as a comparative control. Importantly, the YBX1 dependence of this tRF-mediated response to LNA transfection further supports a role for YBX1 in stabilizing target transcripts through binding of 3' UTR elements (Figure 5D).

Consistent with our proposed tRF-mediated transcript displacement model, we also observed that transfecting tRF mimetics into cells followed by YBX1 co-immunoprecipitation depleted HMGA1, TIMP3, and CD97 transcripts from the YBX1-bound RNA population (Figure 5E). This observation further supports direct competition between tRFs and endogenous transcripts for YBX1 binding in vivo.

metastasis (Jürchott et al., 2010; Matsumoto and Bay, 2005; Uchiyama et al., 2006; Wu et al., 2012). Given the role of tRFs in suppressing the expression of YBX1 target genes, we hypothesized that this class of smRNAs may act to suppress cancer progression. For example, a tRF-YBX1 signature based on the average expression of roughly 70 YBX1-bound transcripts with robust modulations in response to anti-sense LNA or tRF mimetic transfections was found to be significantly associated with cancer stage as well as relapse-free survival of patients with breast cancer (Figures S6A and S6B). The entire YBX1-tRF regulon—defined as the subset of endogenous transcripts that are bound by YBX1 in vivo and whose expression is modulated by the transfection of tRF mimetics and anti-sense LNAs in a YBX1-dependent manner—contains hundreds of transcripts, including many known promoters of tumorigenesis and metastasis, such as AKT, EIF4G1, ITGB4, and HMGA1 (Figures 6A and S6C). We also noted highly significant associations between increased expression of multiple tRF-YBX1 targets that are key




Figure 6. YBX1-Binding tRFs Play a Significant Role in Modulating Oncogenes

(A) Competitive displacement of YBX1 from its target transcripts by tRFs resulted in the down-regulation of a large set of oncogenes and metastasis promoter genes.

(B–D) Kaplan-Meier curves for three translation initiation factors that were modulated by tRFs via YBX1 binding (Gyorffy et al., 2012).

(E) Exogenously added tRF mimetics or anti-sense LNAs resulted in a significant increase and decrease in cancer cell invasion, respectively. Shown are the fold-changes in cancer cell invasion for MDA-parental cells transfected with LNAs and MDA-LM2 cells transfected with tRFs. We have also included representative fields from the invasion inserts along with the median of cells observed in each cohort (n = 7–8).

(F) Growth rates (estimated based on an exponential model) under serum-starved conditions for MDA-LM2 cells transfected with tRF mimetics relative to mock-transfected cells (n = 6).

(G) qRT-PCR assays were used to quantify the levels of tRF^{ASP}, tRF^{Glu}, and tRF^{Gly} in metastatic (n = 18) and non-metastatic (n = 9) primary breast cancers.

For comparing growth under serum-starved conditions, two-way ANOVA was used to measure statistical significance. For all other cases, statistical significance was measured using one-tailed Student's t test: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$. Error bars in all panels indicate SEM unless otherwise specified.

sion capacity in vitro (Figures 6E and S6D). Conversely, transfection of tRF mimetics into metastatic MDA-LM2 and CN-LM1a lines significantly reduced cancer cell invasion (Figures 6E and S6D). We also observed a substantial decrease in cell proliferation rate under serum-starved conditions in the presence of these tRFs, further highlighting their roles as components of a general stress-response pathway (Figure 6F). These tRFs were ineffective at suppressing these phenotypes in cells depleted of YBX1—consistent with a required role for YBX1 in modulating these tRF-mediated responses (Figures S6E and S6F).

Importantly, we also detected tRF^{ASP}, tRF^{Glu}, and tRF^{Gly} in RNA samples from

metastatic and non-metastatic primary tumors as well as normal breast tissue. Consistent with a tumor-suppressive role for these tRFs, their levels were significantly lower in breast cancer tissue relative to normal breast tissue (Figure S6G). Moreover, if these specific tRFs suppress metastatic progression, we would expect that there would be a selection for reduced expression of these tRFs during this process. Indeed, we observed a significant trend toward reduced tRF levels in

components of translation initiation (EIF4G1, EIF4EBP1, and EIF3B) and reduced relapse-free survival ($p = 8 \times 10^{-12}$, 1×10^{-16} , and 2×10^{-13} , respectively; n = 3455; Figures 6B–6D). The transcripts of these oncogenes, which play roles in various aspects of cellular function, including translation and cell signaling, were repressed by tRFs in breast cancer cells (Figure 6A). Transfection of anti-sense LNAs targeting the tRFs into MDA-parental and CN-parental cancer cells significantly enhanced cell inva-

metastatic samples compared to primary tumors ($p = 0.003$, $n = 27$; Figure 6G).

To demonstrate the physiological relevance of this hypoxia-induced tRF-YBX1 pathway, we used a reporter driving the expression of luciferase under a hypoxia response promoter (Figure S7A). Consistent with MDA-parental breast cancer cells experiencing hypoxia early in the metastatic process in the lungs of xenografted mice, cells carrying this reporter exhibited induction of the hypoxia-induced pathway 24 hr post-injection (Figure S7B). To probe the *in vivo* expression of tRF-YBX1 targets, we constructed a lentiviral system with firefly luciferase reporter fused to 3' UTRs of CD97 and TIMP3 (tRF-YBX1 targets) as well as MAPK14 (as a control). Consistent with YBX1 stabilizing these transcripts by binding to their 3' UTRs, immediately after injection, we observed a significantly lower luciferase activity for CD97 and TIMP3 3' UTRs in YBX1 knockdown cells (Figure S7C). More importantly, the CD97 and TIMP3 reporters showed significantly lower day 3 to day 0 luciferase activity ratios in control cells compared to YBX1 knockdown cells (Figure S7D). These findings are consistent with the *in vivo* induction of tRFs under hypoxia and the YBX1 dependence of the associated response. It should be highlighted that this reduction was absent in the luciferase reporter carrying the control MAPK14 3' UTR (Figure S7D).

Consistent with the observed clinical associations and our *in vitro* as well as *in vivo* findings, transfection of tRF mimetics and anti-sense LNAs significantly impacted metastatic colonization in *in vivo* lung colonization assays by multiple independent cell lines. MDA-parental cells transfected with anti-sense LNAs exhibited significantly higher metastatic colonization activity relative to cells transfected with scrambled controls (Figures 7A and S7E). Similarly, transfection of inhibitory anti-sense LNAs in CN-parental cells also caused a marked and significant increase in metastatic colonization of the lungs (Figures 7B and S7E). In contrast, exogenous transfection of tRF mimetics into highly metastatic lines (MDA-LM2 and CN-LM1a cells) significantly reduced cancer metastasis to the lungs (Figures 7C, 7D, and S7E). We also tested and validated the impact of tRF modulation on the metastatic activity of a third human breast cancer cell-line—HCC1806 (Figures 7E and S7E). It should be noted that in these *in vivo* lung colonization assays, a clear and significant difference in the normalized signal could be detected early in the *in vivo* experiments (Figure S7F). This early impact on metastasis is in part consistent with the role of tRFs in cancer cell invasion, which is an early determinant of metastatic progression. This early difference persists throughout the experiment despite the dilution of mimetics and anti-sense LNAs (Figure S7G), and the two cohorts fail to converge. Importantly, consistent with a YBX1-dependent mode of action, depleting YBX1 from cancer cells using RNAi made cells insensitive to tRF-mediated modulation of metastatic activity (Figure S7H).

DISCUSSION

By integrating biochemical, molecular, computational, and phenotypic analyses, we have found that a specific set of tRFs functionally engages the oncogenic RNA-binding protein YBX1. These fragments, which contain a CU box motif, post-transcriptionally suppress the expression of YBX1 transcripts

by competitively displacing them from YBX1. We find that YBX1 binds and promotes the stability of a large set of transcripts, thus modulating a large regulon with broad consequences for cellular function. Our study reveals the first comprehensive and *in vivo* interaction map between YBX1, one of the most overexpressed oncogenes observed in human cancer (upregulated in 10% of all cancer versus normal tissue data sets; Oncomine), and its post-transcriptional target transcripts (Lasham et al., 2012; Uchiyama et al., 2006; Wu et al., 2012). A number of these transcripts encode established drivers of oncogenesis, such as EIF4G1, ITGB4, AKT1, and ADAM8. YBX1 stabilization of oncogenic transcripts is mediated by its binding to CU box motifs, which are primarily located in the 3' UTRs of transcripts. The displacement of oncogenic transcripts from YBX1 results in their destabilization and downregulation. Consistent with a tumor-suppressive role for these YBX1-antagonistic smRNAs, their introduction into breast cancer cells inhibited breast cancer growth under serum starvation, cell invasion, and metastasis. Conversely, inhibiting these fragments by anti-sense LNAs enhanced these phenotypes.

This tRF-mediated displacement mechanism of post-transcriptional silencing involving the binding of specific tRFs to YBX1 differs from RNAi-mediated silencing in that small tRNA fragments do not serve as guides for transcript engagement by YBX1. Rather, they competitively displace and thus destabilize YBX1-bound transcripts. Our findings expand the repertoire of endogenous smRNA-mediated post-transcriptional modes of regulation that have been previously described (RNAi, microRNA, and CeRNA; Karaca et al., 2014; Lujambio and Lowe, 2012; Salmena et al., 2011).

Our findings reveal that a specific set of fragments contain tumor-suppressive and metastasis-suppressive activity. We propose that these fragments are generated as a result of oncogenic stress as an internal mechanism for tumor suppression. We speculate that during breast cancer evolution, two mechanisms counter this smRNA-mediated tumor-suppressive mechanism: the first being the evasion of the hypoxia-evoked induction of tumor-suppressive tRFs, and the second being YBX1 upregulation. Consistent with these findings, tRNA fragments were detected at significantly lower levels in metastatic breast cancer relative to non-metastatic cancers, whereas YBX1 is known to be upregulated as a function of cancer progression (Lasham et al., 2012).

We find that the repressive effects of these endogenous tRNA fragments on the abundance and stability of oncogenic transcripts is moderate in scale. Nonetheless, our loss-of-function and gain-of-function studies involving these fragments reveal robust *in vitro* and *in vivo* effects resulting from their modulation in breast cancer. We believe that these effects result from the coordinated post-transcriptional control of a large set of YBX1-dependent oncogenes whose concomitant suppression results in robust phenotypic effects. These observations parallel those seen with microRNAs implicated in cancer progression—moderate post-transcriptional suppressive effects on groups of transcripts involved in common oncogenic processes (Lujambio and Lowe, 2012).

An association between YBX1 and tRNA halves has been previously described (Emara et al., 2010). Transfection of tRNA




Figure 7. YBX1-Binding tRFs Play a Significant Role as Suppressors of Tumor Progression and Metastasis

(A and B) Bioluminescence imaging plot of metastatic lung colonization by MDA-parental and CN-parental cells transfected with synthetic anti-sense LNAs against all four YBX1-binding tRFs. Representative images along with quantification of the area-under-the-curve for each mouse are also included (n = 3–5 in each cohort).

(C and D) Bioluminescence imaging plot of lung metastasis by MDA-LM2 and CN-LM1a cells transfected with the four YBX1-binding tRFs. Representative images and area-under-the-curve quantifications are also included (n = 4–5 in each cohort).

(E) Bioluminescence imaging plot of lung metastasis by HCC1806 cells transfected with the four YBX1-binding tRFs. Representative images and area-under-the-curve quantifications are also included (n = 5 in each cohort).

(F) Schematic of tRF-mediated modulation of invasion and metastatic lung colonization through in vivo titration of YBX1 and the subsequent destabilization of its oncogenic and pro-metastatic targets.

For comparing metastasis colonization assays, two-way ANOVA was used to measure statistical significance. For all other cases, statistical significance is measured using one-tailed Student's t test: *p < 0.05, **p < 0.01, and ***p < 0.001. Error bars in all panels indicate SEM unless otherwise specified.

halves arising from tRNA^{Ala} and tRNA^{Cys} was found to globally inhibit translation. These tRNA halves were found to repress translation by ~30%, and these effects seemed to result from the disengagement of translational initiation factor EIF4G1. Additionally, it was found that the effect of these tRNA halves on translational repression was YBX1 dependent. These tRNA halves were found to interact with YBX1, and both fragments contained a terminal oligoguanine motif. Although molecular mechanisms for the global inhibition of translation by these tRNA halves and their in vivo roles have yet to be delineated,

the authors proposed that these fragments suppress translation by interfering with EIF4G protein in a YBX1-dependent manner. Our findings described here reveal a distinct mechanism of action by a different class of tRFs. The tRFs we have implicated belong to a distinct class of fragments and mediate post-transcriptional destabilization of a specific set of transcripts by directly engaging YBX1 in a sequence-specific manner. Importantly, our observations regarding the downregulation of elongation initiation factors at the transcript level are in agreement with the broad inhibition of translation reported to be induced by a

broader class of tRNA fragments. Moreover, the different mechanisms by which distinct classes of tRFs regulate YBX1-dependent gene expression highlight the significance of this stress-activated regulator in mammalian gene regulation.

Taken together, our findings support a role for endogenous tRFs in destabilizing oncogenic transcripts through their direct binding to YBX1. tRF binding of YBX1 leads to displacement of endogenous oncogenic transcripts from YBX1—resulting in their destabilization (Figure 7F). Based on this model, specific tRFs mediate a unique post-transcriptional gene-expression regulatory program through their engagement of YBX1. It should be noted, however, that the regulatory interactions mediated by tRFs are unlikely to be limited to YBX1, and they likely serve as a component of a larger regulatory network consisting of various RNA-binding proteins and small ncRNAs. We should also point out the possible role of RNA modifications in the functionality of tRNA fragments. Given that extensive base modifications in tRNAs are crucial for their function, future studies should address the potential role of these modifications in tRNA fragments as well. Two lines of evidence in our data suggest a substantial role for these modifications in modulating the regulatory effects of endogenous tRFs. First, although the induction of endogenous tRFs under hypoxia in MDA-parental cells was substantially more modest than exogenous transfection of synthetic tRF mimetics, the ensuing YBX1-dependent downregulation of the tRF-YBX1 regulon was higher in magnitude for endogenous fragments relative to unmodified transfected mimetics. Second, consistent with the possible importance of RNA modifications in tRFs, transfection of anti-sense LNAs that inhibit endogenous fragments was more potent than that of synthetic mimetics in eliciting a regulatory response in the cells. This higher potency of endogenous tRFs relative to synthetic mimetics could be explained by the presence of RNA modifications that are likely to affect the structure, stability, and binding affinity of these fragments.

Although we have shown that the fragments described here modulate specific phenotypes through transcript displacement from YBX1, they may also modulate the activity of additional *trans* factors. From a broader perspective, we speculate that fragments arising from other classes of ncRNAs, such as ribosomal and sno-RNAs, might mediate similar effects by displacing distinct RNA-binding proteins (or other ncRNAs) from their endogenous downstream targets.

EXPERIMENTAL PROCEDURES

Tissue Culture

HEK293T, MDA-MB-231, and CN34 cells and their derived sub-lines, CN-LM1a and MDA-LM2, were cultured in DMEM-based media supplemented with 10% FBS, glutamine, pyruvate, penicillin, streptomycin, and fungizone. RNAi and DNA transfections were performed using Lipofectamine 2000 (Invitrogen) and TransIT-293 (Mirus), respectively.

Exogenous tRF and Anti-Sense LNA Transfection

tRF anti-sense LNA oligonucleotides (Exiqon) or synthetic tRF mimetics (IDT) were transfected using Lipofectamine 2000 in Reduced Serum Media (Life Technologies) for a final concentration of 50 nM consisting of equal parts of each tRF decoy or anti-tRF LNA. After 6 hr of incubation, transfection media were replaced with fresh media. Cells were subjected to *in vitro* and *in vivo*

studies 48 hr after transfection. The sequences for the short and long tRF mimetics are provided in Figure S2B.

Animal Studies

All mouse studies were conducted according to a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at the Rockefeller University.

ACCESSION NUMBERS

The data for high-throughput sequencing and microarray profiling experiments are deposited at GEO under the accession number GSE63605.

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and Extended Experimental Procedures and can be found with this article online at <http://dx.doi.org/10.1016/j.cell.2015.02.053>.

AUTHOR CONTRIBUTIONS

S.F.T. conceived the project and supervised all research. S.F.T., H.G., X.L., H.C.B.N., L.F., and S.Z. wrote the manuscript. H.G., X.L., H.C.B.N., S.Z., and L.F. designed, performed, and analyzed the experiments.

ACKNOWLEDGMENTS

We are grateful to Saeed Tavazoie, Claudio Alarcon, and Alexander Nguyen for their thoughtful comments on this manuscript. We thank Nora Pencheva for insightful discussions on YBX1. We thank C. Zhao, W. Zhang, C. Lai, and S. Dewell of the Rockefeller Genomics Resource Center for assistance with next-generation RNA sequencing and microarray profiling. We also thank H. Molina at Rockefeller Proteomics Resource Center. H.G. was previously supported by an Anderson Cancer Center Fellowship and is currently the recipient of a Ruth L. Kirschstein National Research Service Award from the NIH (T32CA009673-36A1). S.F.T. is a Department of Defense Era of Hope Scholar and a Department of Defense Breast Cancer Collaborative Scholars and Innovators Award recipient.

Received: September 25, 2014

Revised: January 9, 2015

Accepted: February 27, 2015

Published: May 7, 2015

REFERENCES

- Borek, E., Baliga, B.S., Gehrke, C.W., Kuo, C.W., Belman, S., Troll, W., and Waalkes, T.P. (1977). High turnover rate of transfer RNA in tumor tissue. *Cancer Res.* 37, 3362–3366.
- Bristow, R.G., and Hill, R.P. (2008). Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. *Nat. Rev. Cancer* 8, 180–192.
- Cole, C., Sobala, A., Lu, C., Thatcher, S.R., Bowman, A., Brown, J.W.S., Green, P.J., Barton, G.J., and Hutvagner, G. (2009). Filtering of deep sequencing data reveals the existence of abundant Dicer-dependent small RNAs derived from tRNAs. *RNA* 15, 2147–2160.
- Elemento, O., Slonim, N., and Tavazoie, S. (2007). A universal framework for regulatory element discovery across all genomes and data types. *Mol. Cell* 28, 337–350.
- Emara, M.M., Ivanov, P., Hickman, T., Dawra, N., Tisdale, S., Kedersha, N., Hu, G.F., and Anderson, P. (2010). Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. *J. Biol. Chem.* 285, 10959–10968.
- Fu, H., Feng, J., Liu, Q., Sun, F., Tie, Y., Zhu, J., Xing, R., Sun, Z., and Zheng, X. (2009). Stress induces tRNA cleavage by angiogenin in mammalian cells. *FEBS Lett.* 583, 437–442.

- Gebetsberger, J., and Polacek, N. (2013). Slicing tRNAs to boost functional ncRNA diversity. *RNA Biol.* *10*, 1798–1806.
- Gyorffy, B., Lanczy, A., and Szallasi, Z. (2012). Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. *Endocr. Relat. Cancer* *19*, 197–208.
- Ivanov, P., Emara, M.M., Villen, J., Gygi, S.P., and Anderson, P. (2011). Angiogenin-induced tRNA fragments inhibit translation initiation. *Mol. Cell* *43*, 613–623.
- Jurchott, K., Kuban, R.J., Krech, T., Bluthgen, N., Stein, U., Walther, W., Friese, C., Kietbasa, S.M., Ungethum, U., Lund, P., et al. (2010). Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. *PLoS Genet.* *6*, e1001231.
- Karaca, E., Weitzer, S., Pehlivan, D., Shiraishi, H., Gogakos, T., Hanada, T., Jhangiani, S.N., Wiszniewski, W., Withers, M., Campbell, I.M., et al.; Baylor Hopkins Center for Mendelian Genomics (2014). Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. *Cell* *157*, 636–650.
- Krol, J., Loedige, I., and Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function and decay. *Nat. Rev. Genet.* *11*, 597–610.
- Lasham, A., Samuel, W., Cao, H., Patel, R., Mehta, R., Stern, J.L., Reid, G., Woolley, A.G., Miller, L.D., Black, M.A., et al. (2012). YB-1, the E2F pathway, and regulation of tumor cell growth. *J. Natl. Cancer Inst.* *104*, 133–146.
- Lee, Y.S., Shibata, Y., Malhotra, A., and Dutta, A. (2009). A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). *Genes & Development* *23*, 2639–2649.
- Lujambio, A., and Lowe, S.W. (2012). The microcosmos of cancer. *Nature* *482*, 347–355.
- Matsumoto, K., and Bay, B.H. (2005). Significance of the Y-box proteins in human cancers. *J. Mol. Genet. Med.* *1*, 11–17.
- Minn, A.J., Gupta, G.P., Siegel, P.M., Bos, P.D., Shu, W., Giri, D.D., Viale, A., Olshen, A.B., Gerald, W.L., and Massague, J. (2005). Genes that mediate breast cancer metastasis to lung. *Nature* *436*, 518–524.
- Moyer, M.W. (2012). Targeting hypoxia brings breath of fresh air to cancer therapy. *Nat. Med.* *18*, 636–637.
- Salmena, L., Poliseno, L., Tay, Y., Kats, L., and Pandolfi, P.P. (2011). A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? *Cell* *146*, 353–358.
- Semenza, G.L. (1999). Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1. *Annu. Rev. Cell Dev. Biol.* *15*, 551–578.
- Shen, C., and Kaelin, W.G., Jr. (2013). The VHL/HIF axis in clear cell renal carcinoma. *Semin. Cancer Biol.* *23*, 18–25.
- Speer, J., Gehrke, C.W., Kuo, K.C., Waalkes, T.P., and Borek, E. (1979). tRNA breakdown products as markers for cancer. *Cancer* *44*, 2120–2123.
- Thompson, D.M., and Parker, R. (2009). Stressing out over tRNA cleavage. *Cell* *138*, 215–219.
- Uchiumi, T., Fotovati, A., Sasaguri, T., Shibahara, K., Shimada, T., Fukuda, T., Nakamura, T., Izumi, H., Tsuzuki, T., Kuwano, M., and Kohno, K. (2006). YB-1 is important for an early stage embryonic development: neural tube formation and cell proliferation. *J. Biol. Chem.* *281*, 40440–40449.
- Ule, J., Jensen, K., Mele, A., and Darnell, R.B. (2005). CLIP: a method for identifying protein-RNA interaction sites in living cells. *Methods* *37*, 376–386.
- Wilson, W.R., and Hay, M.P. (2011). Targeting hypoxia in cancer therapy. *Nat. Rev. Cancer* *11*, 393–410.
- Wu, Y., Yamada, S., Izumi, H., Li, Z., Shimajiri, S., Wang, K.Y., Liu, Y.P., Kohno, K., and Sasaguri, Y. (2012). Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer. *J. Surg. Oncol.* *105*, 724–730.
- Zhang, C.L., and Darnell, R.B. (2011). Mapping in vivo protein-RNA interactions at single-nucleotide resolution from HITS-CLIP data. *Nat. Biotechnol.* *29*, 607–614.